Julie Nangia, MD
Hematology & Oncology · Houston, TXNPI 1164684213
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,998 of the $10,997 with a category attached, or 72.7%. 9 manufacturers reported payments, led by Novartis at 34.0% of the total.
Across 54 payments — averaging $203.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$4K
- Gilead$3K
- Tersera Therapeutics LLC$3K
- Pfizer$244
- Puma Biotechnology, Inc.$227
- Genentech USA, Inc.$142
- plus $114 from 3 others
Across 12 payments — averaging $20,213 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$194K
- AstraZeneca$23K
- Tesaro, Inc.$22K
- Merck$3K
What the payments were for
- Consulting fees$7,99873%
- Travel & lodging$1,0079%
- Food & beverage$1,19411%
- Education$3003%
- Other$4995%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $3,744 |
| Gilead | 8 | $3,494 |
| Tersera Therapeutics LLC | 6 | $3,031 |
| Pfizer | 23 | $244 |
| Puma Biotechnology, Inc. | 3 | $227 |
| Genentech USA, Inc. | 1 | $142 |
| AstraZeneca | 2 | $70 |
| Merck | 1 | $22 |
| Amgen | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,997 in reported general payments places this provider in the 70th percentile of 838 hematology & oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 47 | $1,327 |
| Raloxifene Hcl | 26 | $1,206 |
| Tamoxifen Citrate | 36 | $898 |
| Exemestane | 12 | $650 |
| Alendronate Sodium | 13 | $195 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Houston
- Devesh PandyaHouston$1.8M
- Elias JabbourHouston$1.3M
- Naval DaverHouston$853K
- Jorge Cortes-FrancoHouston$627K
- Courtney DinardoHouston$478K
- Prithviraj BoseHouston$463K
- Milind JavleHouston$326K
- Loretta NastoupilHouston$309K
- Boyu HuHouston$281K
- Luis CamachoHouston$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.